Literature DB >> 32861290

Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma.

Priyanka A Pophali1, Gita Thanarajasingam2.   

Abstract

Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients' health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients' lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse events; Chronic therapy; HRQOL; Mantle cell lymphoma; Patient-reported outcomes; Toxicity

Year:  2020        PMID： 32861290      PMCID： PMC7459143          DOI： 10.1016/j.hoc.2020.06.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  40 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

Review 3.  International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Authors:  Corneel Coens; Madeline Pe; Amylou C Dueck; Jeff Sloan; Ethan Basch; Melanie Calvert; Alicyn Campbell; Charles Cleeland; Kim Cocks; Laurence Collette; Nancy Devlin; Lien Dorme; Hans-Henning Flechtner; Carolyn Gotay; Ingolf Griebsch; Mogens Groenvold; Madeleine King; Paul G Kluetz; Michael Koller; Daniel C Malone; Francesca Martinelli; Sandra A Mitchell; Jammbe Z Musoro; Daniel O'Connor; Kathy Oliver; Elisabeth Piault-Louis; Martine Piccart; Chantal Quinten; Jaap C Reijneveld; Christoph Schürmann; Ashley Wilder Smith; Katherine M Soltys; Martin J B Taphoorn; Galina Velikova; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2020-02       Impact factor: 41.316

4.  Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

Authors:  Kirit M Ardeshna; Wendi Qian; Paul Smith; Nivette Braganca; Lisa Lowry; Pip Patrick; June Warden; Lindsey Stevens; Christopher F E Pocock; Fiona Miall; David Cunningham; John Davies; Andrew Jack; Richard Stephens; Jan Walewski; Burhan Ferhanoglu; Ken Bradstock; David C Linch
Journal:  Lancet Oncol       Date:  2014-03-04       Impact factor: 41.316

5.  A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.

Authors:  Fay J Hlubocky; Kimberly Webster; Jennifer Beaumont; John Cashy; Diane Paul; Amy Abernethy; Karen L Syrjala; Jamie Von Roenn; David Cella
Journal:  Leuk Lymphoma       Date:  2013-02-07

Review 6.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

7.  Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy.

Authors:  F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

8.  Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

Authors:  Melanie Calvert; Derek Kyte; Rebecca Mercieca-Bebber; Anita Slade; An-Wen Chan; Madeleine T King; Amanda Hunn; Andrew Bottomley; Antoine Regnault; An-Wen Chan; Carolyn Ells; Daniel O'Connor; Dennis Revicki; Donald Patrick; Doug Altman; Ethan Basch; Galina Velikova; Gary Price; Heather Draper; Jane Blazeby; Jane Scott; Joanna Coast; Josephine Norquist; Julia Brown; Kirstie Haywood; Laura Lee Johnson; Lisa Campbell; Lori Frank; Maria von Hildebrand; Michael Brundage; Michael Palmer; Paul Kluetz; Richard Stephens; Robert M Golub; Sandra Mitchell; Trish Groves
Journal:  JAMA       Date:  2018-02-06       Impact factor: 56.272

9.  How to report toxicity associated with targeted therapies?

Authors:  B Cabarrou; J M Boher; E Bogart; E Tresch-Bruneel; N Penel; A Ravaud; B Escudier; C Mahier Ait-Oukhatar; J P Delord; H Roché; T Filleron
Journal:  Ann Oncol       Date:  2016-05-23       Impact factor: 32.976

10.  Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.

Authors:  Gita Thanarajasingam; Pamela J Atherton; Paul J Novotny; Charles L Loprinzi; Jeff A Sloan; Axel Grothey
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.